Skip NavigationSkip to Content
Return Return to Search Results

Heterodimeric IL-15 in Cancer Immunotherapy

  1. Author:
    Bergamaschi,Cristina
    Stravokefalou,Vasiliki
    Stellas,Dimitris
    Karaliota,Sevasti
    Felber,Barbara
    Pavlakis,George

  2. Author Address

    Natl Canc Inst Frederick, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA.Natl Canc Inst Frederick, Human Retrovirus Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA.Frederick Natl Lab Canc Res, Basic Sci Program, Frederick, MD 21702 USA.
    1. Year: 2021
    2. Date: Feb 17
    3. Epub Date: 2021 02 17
  2. Journal: Cancers
  3. MDPI,
    1. 13
    2. 4
  5. Type of Article: Review
  6. Article Number: ARTN 837
  7. ISSN: 2072-6694
  1. Abstract:

    Immunotherapy has emerged as a valuable strategy for the treatment of many cancer types. Interleukin-15 (IL-15) promotes the growth and function of cytotoxic CD8+ T and natural killer (NK) cells. It also enhances leukocyte trafficking and stimulates tumor-infiltrating lymphocytes expansion and activity. Bioactive IL-15 is produced in the body as a heterodimeric cytokine, comprising the IL-15 and the so-called IL-15 receptor alpha chain that are together termed "heterodimeric IL-15" (hetIL-15). hetIL-15, closely resembling the natural form of the cytokine produced in vivo, and IL-15:IL-15Ra complex variants, such as hetIL-15Fc, N-803 and RLI, are the currently available IL-15 agents. These molecules have showed favorable pharmacokinetics and biological function in vivo in comparison to single-chain recombinant IL-15. Preclinical animal studies have supported their anti-tumor activity, suggesting IL-15 as a general method to convert "cold" tumors into "hot", by promoting tumor lymphocyte infiltration. In clinical trials, IL-15-based therapies are overall well-tolerated and result in the expansion and activation of NK and memory CD8+ T cells. Combinations with other immunotherapies are being investigated to improve the anti-tumor efficacy of IL-15 agents in the clinic.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/cancers13040837
  3. PMID: 33671252
  4. PMCID: PMC7922495
  5. View record in Web of Science®
  6. WOS: 000623339500001

Library Notes

  1. Open Access Publication
  2. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel